Skip to main
RAPT
RAPT logo

RAPT Stock Forecast & Price Target

RAPT Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

RAPT Therapeutics is well-positioned for future growth due to its innovative pipeline, particularly the RPT904 and JYB1904 programs, which could showcase differentiated efficacy in 2025, enhancing market interest. The company's RPT904, featuring a commercially validated mechanism of action with improved pharmacokinetics and half-life, represents a significant and de-risked opportunity in the immunologic and asthmatic markets. Additionally, the recent acquisition of Verona Pharma by Merck highlights the increasing value and focus within the pharmaceutical sector on immunology and inflammation therapeutics, potentially benefiting RAPT's strategic positioning.

Bears say

RAPT Therapeutics faces significant risks that contribute to a negative outlook, including the potential for safety signals to emerge from clinical or preclinical programs, which could adversely affect investor confidence. Additionally, the company may encounter challenges regarding the efficacy of its clinical programs, particularly if studies do not achieve the anticipated statistical significance, further complicating its development path. The company's financial health is also a concern, as it requires substantial financing estimated at approximately $1.1 billion through 2040, alongside a limited cash runway projected only until 2027.

RAPT has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapt Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapt Therapeutics Inc (RAPT) Forecast

Analysts have given RAPT a Buy based on their latest research and market trends.

According to 9 analysts, RAPT has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapt Therapeutics Inc (RAPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.